Ratings by HSBC (Rajesh Kumar)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2026 | IQVIA Holdings | IQV | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2026 | Danaher | DHR | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2026 | Eli Lilly | LLY | Downgrade | Reduce (Hold) |
985.08 (1111.60) |
12.84% | Details | |
| 3/10/2026 | Pfizer | PFE | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Hold (N/A) |
|
Details | ||
| 3/10/2026 | Biogen | BIIB | Maintain | Reduce (N/A) |
|
Details | ||
| 12/10/2025 | Biogen | BIIB | Downgrade | Reduce (Hold) |
180.44 (198.59) |
10.06% | Details | |
| 12/10/2025 | Abbvie | ABBV | Upgrade | Buy (Hold) |
223.12 (231.59) |
3.8% | Details | |
| 12/1/2025 | IQVIA Holdings | IQV | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2025 | Danaher | DHR | Maintain | Buy (N/A) |
|
Details | ||
| 10/9/2025 | IQVIA Holdings | IQV | Upgrade | Buy (Hold) |
200.86 (167.54) |
-16.59% | Details | |
| 10/1/2025 | Abbvie | ABBV | Downgrade | Hold (Buy) |
231.54 (231.59) |
0.02% | Details | |
| 8/27/2025 | Eli Lilly | LLY | Upgrade | Hold (Reduce) |
736.03 (985.08) |
33.84% | Details | |
| 4/28/2025 | Eli Lilly | LLY | Downgrade | Reduce (Buy) |
859.73 (736.03) |
-14.39% | Details | |
| 4/28/2025 | Biogen | BIIB | Downgrade | Hold (Buy) |
119.51 (198.59) |
66.17% | Details | |
| 4/25/2025 | IQVIA Holdings | IQV | Downgrade | Hold (Buy) |
147.06 (200.86) |
36.58% | Details | |
| 12/4/2024 | Novartis | NVS | Downgrade | Reduce (Hold) |
104.56 (149.13) |
42.63% | Details | |
| 12/4/2024 | Merck | MRK | Upgrade | Buy (Hold) |
100.61 (115.22) |
14.52% | Details | |
| 12/4/2024 | IQVIA Holdings | IQV | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2024 | Gilead Sciences | GILD | Maintain | Hold (N/A) |
|
Details | ||
| 6/5/2024 | Abbvie | ABBV | Upgrade | Buy (Hold) |
160.19 (231.59) |
44.57% | Details | |
| 4/4/2024 | UnitedHealth Group | UNH | Upgrade | Hold (Reduce) |
459.74 (408.67) |
-11.11% | Details | |
| 12/18/2023 | UnitedHealth Group | UNH | Downgrade | Reduce (Hold) |
534.24 (408.67) |
-23.5% | Details | |
| 12/18/2023 | Abbvie | ABBV | Downgrade | Hold (Buy) |
154.88 (231.59) |
49.53% | Details | |
| 12/18/2023 | Thermo Fisher Scientific | TMO | New Coverage | Buy (N/A) |
521.52 (464.44) |
-10.94% | Details | |
| 12/18/2023 | Teva Pharma | TEVA | New Coverage | Buy (N/A) |
10.23 (32.14) |
214.17% | Details | |
| 12/18/2023 | Danaher | DHR | New Coverage | Hold (N/A) |
229.25 (179.10) |
-21.88% | Details | |
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Upgrade | Hold (Reduce) |
56.61 (54.61) |
-3.53% | Details | |
| 9/15/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Reduce (N/A) |
|
Details | ||
| 7/14/2023 | Sanofi-Aventis | SNY | New Coverage | Buy (N/A) |
51.83 (41.59) |
-19.76% | Details |
